Pfizer have chosen the preferred once-daily modified release form of danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist.

This submission seeks regulatory approval through the Therapeutic Goods Administration (TGA)’s Clinical Trial Notification scheme to initiate a first-in-human Phase 1 clinical trial for SAT-3247.

Context Therapeutics Inc. has publicized the acquisition of CT-95, previously the property of Link Immunotherapeutics, Inc.

Skyhawk Therapeutics Reports Positive Topline Results from Phase 1 Trial of SKY-0515 for Huntington’s Disease, Achieving 72% Reduction in Huntingtin mRNA.

MEKanistic Therapeutics Inc.’s innovative dual-target therapy, MTX-531, shows considerable tolerability and sustained tumor reduction in preclinical cancer studies.

Rgenta Therapeutics secures FDA nod for IND application of RGT-61159, an oral RNA modulator intended to stop MYB production, targeting Adenoid Cystic Carcinoma (ACC) and Colorectal Cancer (CRC).

Avalo Therapeutics Reports IND Activation for AVTX-009, an anti-IL-1β Antibody, Aimed at Treating Hidradenitis Suppurativa.

uniQure Releases Promising Interim Results Showing Reduced Disease Progression in Phase I/II AMT-130 Trials for Huntington’s Disease.

The agreement specifies that the Phase 2 clinical trial will evaluate the effectiveness of PRT37890, a new and highly selective SMARCA2 degrader, and Merck's KEYTRUDA in treating cancers with SMARCA4 mutations.

Kiniksa Pharmaceuticals International announced that it has begun enrolling participants for the Phase 2b clinical trial of abiprubart in Sjögren’s Disease.

AEON Biopharma revealed their intention to proceed with a crucial clinical development trial in cervical dystonia for their main product, ABP-450 (prabotulinumtoxinA) injection.

Eli Lilly and Company along with Morphic Holding, Inc. have revealed a formal agreement in which Lilly will purchase Morphic.